Atazanavir Sulfate

證據等級: L5

預測適應症: 0 個

Atazanavir Sulfate: HIV Protease Inhibitor — Repurposing Analysis Pending

One-Sentence Summary

Atazanavir Sulfate is an antiretroviral protease inhibitor used in combination therapy for HIV-1 infection. This evidence pack contains no TxGNN repurposing predictions, and critical drug-level data — including mechanism of action, licence details, and safety warnings — are absent. A full repurposing evaluation cannot be completed until the identified data gaps are resolved.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (combination antiretroviral therapy)
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Note: The Clinical Trial Evidence, Literature Evidence, and “Why is This Prediction Reasonable?” sections are omitted because predicted_indications is empty in this evidence pack. Once TxGNN predictions are generated, those sections will be populated automatically.

Malaysia Market Information

The NPRA query confirmed 1 registered product with a market status of Marketed. However, all product-level fields (licence number, product name, dosage form, manufacturer, approved indication) were returned as empty strings in this evidence pack and cannot be displayed.

Authorisation Number	Product Name	Dosage Form	Approved Indication
—	—	—	—

Detailed registration data should be retrieved directly from the NPRA Product Registration Search.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions are present in this evidence pack, and key drug-level and regulatory data are missing — making any meaningful repurposing evaluation impossible at this stage.

To proceed, the following is needed:

Run TxGNN prediction pipeline for Atazanavir Sulfate to generate candidate repurposing indications
Populate DrugBank data (MOA, drug categories, known interactions) — the DrugBank query returned 1 result but no fields were captured; the DrugBank entry for atazanavir is DB01072
Download and parse the NPRA / TFDA package insert PDF to extract warnings, contraindications, and the officially approved indication text (Data Gap DG001 — classified as Blocking)
Re-query the NPRA product register to retrieve licence number, product name, dosage form, and manufacturer details for the 1 confirmed registration
Resolve MOA data gap (DG002) via DrugBank API to enable mechanistic plausibility analysis for any predicted indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.